Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Diabetic Peripheral Neuropathic Pain: early-phase trial registry

5 of 8 indexed Diabetic Peripheral Neuropathic Pain trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 5 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Diabetic Peripheral Neuropathic Pain: 8 US clinical trials tracked, 5 recruiting.

Diabetic Peripheral Neuropathic Pain is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Vertex Pharmaceuticals Incorporated, running 4 of these trials.

Enrollment posture brief

Registry condition diabetic-peripheral-neuropathic-pain

OPEN 5 | RECR 63% | LATE 3 | EARLY 5 | RANK #2176 | SPON 4

Nearest open-share peer: Adolescent (63% recruiting · 16 trials)

Activity, Motor75%Diabetic Peripheral Neur (th…63%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Diabetic Peripheral Neuropathic Pain

Diabetic Peripheral Neuropathic Pain lists 5 open slots (63% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetic Peripheral Neuropathic Pain on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetic Peripheral Neuropathic Pain is recruiting above its size-band peers.

    5 of 8 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Diabetic Peripheral Neuropathic Pain research.

    Vertex Pharmaceuticals Incorporated accounts for 4 of 8 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetic Peripheral Neuropathic Pain enrolment sits around 300 participants.

    Median target enrolment is 300 among the 8 trials that report a genuine target (sentinel values excluded). 1 of those (12.5%) plan for fewer than 100 participants.

  4. Diabetic Peripheral Neuropathic Pain research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 24Phase 33

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 3 1,100 participants

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

Vertex Pharmaceuticals Incorporated

NCT06628908

RECRUITING Phase 3 734 participants

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

Vertex Pharmaceuticals Incorporated

NCT07231419

RECRUITING Phase 2 300 participants

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Vertex Pharmaceuticals Incorporated

NCT06619860

RECRUITING Phase 2 150 participants

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

Eli Lilly and Company

NCT07285018

RECRUITING Phase 1 24 participants

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

Zhejiang Hanmai Pharmaceutical Technology Co.

NCT06361108

ACTIVE NOT RECRUITING Phase 3 455 participants

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

Vertex Pharmaceuticals Incorporated

NCT06696443

COMPLETED Phase 2 167 participants

Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

Eliem Therapeutics (UK)

NCT04688671

COMPLETED Phase 2 131 participants

A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

Eli Lilly and Company

NCT05620576

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 3

Named interventions

Most-linked intervention names on Diabetic Peripheral Neuropathic Pain records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Suzetrigine Drug
3 trials
Placebo Drug
3 trials
Placebo (matched to SUZ) Drug
2 trials
Pregabalin Drug
2 trials
LY3857210 Drug
1 trials
ETX-018810 Drug
1 trials
LY4065967 Drug
1 trials
Placebo (matched to Pregabalin) Drug
1 trials

US sites by state

Facility locations filed on Diabetic Peripheral Neuropathic Pain trials. A trial with sites in several states counts in each.

Florida 7 trials
California 7 trials
Arizona 6 trials
Georgia 5 trials
Alabama 5 trials
Missouri 4 trials
Colorado 4 trials
Michigan 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetic Peripheral Neuropathic Pain page

8 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Peripheral Neuropathic Pain condition card totals 8 registered trials; most-linked intervention Suzetrigine; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.